{"id":22502,"date":"2023-04-28T17:50:33","date_gmt":"2023-04-28T12:20:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=22502"},"modified":"2023-05-24T09:32:47","modified_gmt":"2023-05-24T04:02:47","slug":"roche-polivy-adc-for-dlbcl-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment","title":{"rendered":"Roche\u2019s CD79b ADC POLIVY: Attempt to Change DLBCL Treatment Space"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e2e38678d3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e2e38678d3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\/#POLIVY_in_RR_DLBCL_setting\" >POLIVY in R\/R DLBCL setting<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\/#POLIVY_takes_the_lead_in_1L_DLBCL_treatment_Substitute_for_the_Oncovin_O_component_of_the_R-CHOP_regimen\" >POLIVY takes the lead in 1L DLBCL treatment. Substitute for the Oncovin (O) component of the R-CHOP regimen?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\/#Scrutiny_by_the_FDA\" >Scrutiny by the FDA&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\/#POLIVYs_share_expected_to_decline_in_later_lines_Competition_arises\" >POLIVY\u2019s share expected to decline in later lines. Competition arises.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of <a href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\"><strong>antibody-drug conjugates (ADCs)<\/strong><\/a><strong>.<\/strong> These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them together. The result is a powerful therapeutic agent that can precisely target cancer cells, delivering its potent payload with surgical precision.&nbsp;<\/p>\n\n\n\n<p>Currently, two ADCs have received<strong> approval for the treatment of DLBCL, <\/strong>namely<strong> Roche\u2019s POLIVY <\/strong>and<strong> ADC Therapeutics\u2019 ZYLNONTA. <\/strong>ZYLNONTA and POLIVY + bendamustine and rituximab (BR) are likely preferable DLBCL treatments for people with primary resistance.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130507\/POLIVY-vs.-ZYLNONTA-US-Approval-Timeline.png\" alt=\"POLIVY vs. ZYLNONTA US Approval Timeline\" class=\"wp-image-22519\" width=\"692\" height=\"281\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130507\/POLIVY-vs.-ZYLNONTA-US-Approval-Timeline.png 923w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130507\/POLIVY-vs.-ZYLNONTA-US-Approval-Timeline-300x122.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130507\/POLIVY-vs.-ZYLNONTA-US-Approval-Timeline-150x61.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130507\/POLIVY-vs.-ZYLNONTA-US-Approval-Timeline-768x312.png 768w\" sizes=\"(max-width: 692px) 100vw, 692px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-polivy-in-r-r-dlbcl-setting\"><span class=\"ez-toc-section\" id=\"POLIVY_in_RR_DLBCL_setting\"><\/span><strong>POLIVY in R\/R DLBCL setting<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>POLIVY is the only ADC in DLBCL targeting CD79b<\/strong> and delivers monomethyl auristatin E, a microtubule inhibitor (MMAE). <strong>POLIVY<\/strong> is presently authorized as a widely accessible, fixed-duration therapy option for R\/R DLBCL in combination with BR, following at least two prior therapies in more than <strong>80 nations and <\/strong>regions around the world, including the US and Europe. As monotherapy or in combination with a regimen containing an anti-CD20 monoclonal antibody, POLIVY has demonstrated encouraging efficacy for R\/R DLBCL.<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"624\">\n\t<colgroup>\n\t\t<col width=\"126\">\n\t\t<col width=\"116\">\n\t\t<col width=\"130\">\n\t\t<col width=\"126\">\n\t\t<col width=\"126\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"5\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#bfe6ff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Results from Phase I\/II trial comparing POLIVY + BR and BR alone<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">&nbsp;<\/td>\n\t\t\t<td rowspan=\"3\" style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:116px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase I\/II trial (NCT02257567)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:130px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Number of Patients&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ORR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CRR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">POLIVY + BR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:116px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#ffffff\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">40<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:130px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">45%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#ffffff\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">&nbsp;40%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">BR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:116px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">40<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:130px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">17.5%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">17.5%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td colspan=\"5\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:126px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Note: ORR: <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Overall response rate<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">, CRR: <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Complete response rate<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"POLIVY_takes_the_lead_in_1L_DLBCL_treatment_Substitute_for_the_Oncovin_O_component_of_the_R-CHOP_regimen\"><\/span><strong>POLIVY takes the lead in 1L DLBCL treatment. Substitute for the Oncovin (O) component of the R-CHOP regimen?&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In March 2023, FDA\u2019s Oncologic Drugs Advisory Committee voted 11 to 2 in favor of the clinical benefit of the <a href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-vs-adc-therapeutics-zynlonta-adc-in-rr-dlbcl\"><strong>Phase III POLARIX study<\/strong> of POLIVY + R-CHP for 1L DLBCL treatment<\/a>. After the Phase III POLARIX study provided crucial data, Roche successfully obtained approval for the use of <strong>POLIVY + R-CHP<\/strong> in DLBCL treatment in the <strong>United States on April 19, 2023<\/strong>. This marks the end of a nearly two-decade-long period of clinical practice, which is expected to undergo a significant shift due to this development. Despite previous regulatory concerns, Roche\u2019s efforts have paid off, and combination therapy is anticipated to be widely adopted.<\/p>\n\n\n\n<p>The combination of <strong>POLIVY + R-CHP <\/strong>has been approved for 1L DLBCL treatment in over <strong>60<\/strong> <strong>countries<\/strong>, including the <strong>EU<\/strong>, <strong>UK<\/strong>,<strong> Japan<\/strong>,<strong> Canada<\/strong>, and <strong>China<\/strong>. This DLBCL treatment option has also been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a preferred category 1 regimen for DLBCL in the first-line setting.Therefore, out of all the <a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-pipeline-insight\">emerging therapies in 1L DLBCL<\/a>, DelveInsight expects the POLIVY + R-CHP combination to lead with a peak revenue of approximately <strong>USD 950 million<\/strong> in the United States by 2032. POLIVY + R-CHP shows a statistically significant reduction in the risk of disease worsening or death compared to R-CHOP after a median follow-up of 3 years. According to the <strong>POLARIX trial data, POLIVY + R-CHP <\/strong>is showing better PFS than R-CHOP alone. POLIVY plus R-CHP response rates are significant.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28124507\/Polivy-expected-to-share-market-with-other-class-of-therapies-in-first-line-setting-1024x544.png\" alt=\"Polivy expected to share market with other class of therapies in first-line setting\" class=\"wp-image-22504\" width=\"768\" height=\"408\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28124507\/Polivy-expected-to-share-market-with-other-class-of-therapies-in-first-line-setting-1024x544.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28124507\/Polivy-expected-to-share-market-with-other-class-of-therapies-in-first-line-setting-300x159.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28124507\/Polivy-expected-to-share-market-with-other-class-of-therapies-in-first-line-setting-150x80.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28124507\/Polivy-expected-to-share-market-with-other-class-of-therapies-in-first-line-setting-768x408.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28124507\/Polivy-expected-to-share-market-with-other-class-of-therapies-in-first-line-setting.png 1170w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Scrutiny_by_the_FDA\"><\/span><strong>Scrutiny by the FDA&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA scrutinized the data of POLARIX, examining the results in various patient subgroups. Upon analysis, the FDA discovered that <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-lymphomas-market\">high-grade B-cell lymphoma patients<\/a> mostly drove the enhancement in progression-free survival, while <a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\">patients with DLBCL<\/a>, which was the most extensive subgroup, experienced minimal benefit.&nbsp;In the future, the willingness of physicians to prescribe POLIVY + R-CHP as first-line therapy will also be a key factor in winning over patients in the 1L setting. However, POLIVY + R-CHP&#8217;s acceptance may be affected in first-line DLBCL treatment due to the lack of an OS benefit<strong>.<\/strong><\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"624\">\n\t<colgroup>\n\t\t<col width=\"118\">\n\t\t<col width=\"113\">\n\t\t<col width=\"106\">\n\t\t<col width=\"99\">\n\t\t<col width=\"99\">\n\t\t<col width=\"89\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"6\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#bfe6ff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Results from the Phase III trial comparing POLIVY + R-CHP and R-CHOP<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:118px\">&nbsp;<\/td>\n\t\t\t<td rowspan=\"3\" style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:113px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase III trial<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">(NCT03274492)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:106px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Number of Patients&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:99px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ORR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:99px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CRR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:89px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">2 years OS<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">POLIVY + R-CHP<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:113px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#ffffff\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">440<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:106px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">85.5%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:99px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#ffffff\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">78.0%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:99px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#ffffff\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">88.7%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">R-CHOP<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:113px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">439<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:106px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#f2f2f2\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">83.8%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:99px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">74.0%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:99px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#f2f2f2\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">88.6%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"POLIVYs_share_expected_to_decline_in_later_lines_Competition_arises\"><\/span><strong>POLIVY\u2019s share expected to decline in later lines. Competition arises.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>After its<strong> <\/strong>approval in the first-line setting, POLIVY<strong> <\/strong>is expected to<strong> <\/strong>gain a significant<strong> <\/strong>portion of the<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\">DLBCL treatment market share<\/a>.<strong> <\/strong>Nevertheless, it is<strong> <\/strong>anticipated that<strong> <\/strong>in the<strong> <\/strong>second and third-line settings, POLIVY&#8217;s market share will decrease.<strong> <\/strong>As a result,<strong> ZYNLONTA <\/strong>is<strong> <\/strong>expected to maintain a stable share<strong> <\/strong>of<strong> <\/strong>patients for a few years while competition in the third-line and beyond settings grows. ZYNLONTA may be more tolerable than POLIVY-BR, but both would be effective. ZYNLONTA is approved in the US and currently has a favorable CHMP (Committee for Medicinal Products for Human Use) opinion adopted in Europe.<strong> <\/strong>The third line is getting quite crowded, and the only hope in this situation is outstanding efficacy and safety data; thus, ZYNLONTA needs to expand into markets other than the United States and earlier lines. ZYNLONTA is likely to face competition from other ADCs, as well as from <a href=\"https:\/\/www.delveinsight.com\/blog\/emergence-of-bispecific-antibodies-in-dlbcl\">upcoming bi-specific antibodies<\/a> and monoclonal antibodies such as MONJUVI.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/diffuse-large-b-cell-lymphoma-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125624\/Diffuse-Large-B-cell-Lymphoma-Infographics.png\" alt=\"Diffuse Large B-cell Lymphoma Infographics\" class=\"wp-image-22507\" width=\"460\" height=\"271\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125624\/Diffuse-Large-B-cell-Lymphoma-Infographics.png 613w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125624\/Diffuse-Large-B-cell-Lymphoma-Infographics-300x177.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125624\/Diffuse-Large-B-cell-Lymphoma-Infographics-150x88.png 150w\" sizes=\"(max-width: 460px) 100vw, 460px\" \/><\/a><\/figure>\n\n\n\n<p><strong>ADC Therapeutics<\/strong> is developing a comprehensive program for DLBCL, which includes the <strong>Phase III LOTIS-5 <\/strong>study of ZYNLONTA combined with rituximab in 2L non-transplant eligible patients and is expected to read out data in mid-2025 and could potentially provide an advantage to ZYNLONTA over MONJUVI. Additionally, ADC Therapeutics is conducting a <strong>Phase II LOTIS-3<\/strong> <strong>trial <\/strong>of ZYNLONTA in combination with ibrutinib, which has demonstrated encouraging results in non-GCB DLBCL. The data from this trial is anticipated in mid-2025 and could further solidify ZYLONTA\u2019s position.&nbsp;<\/p>\n\n\n\n<p>After the <a href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-vs-adc-therapeutics-zynlonta-adc-in-rr-dlbcl\">approval of POLIVY and ZYNLONTA<\/a> in 3L+, several companies have shifted their focus on developing ADCs for R\/R DLBCL treatment, such as <strong>Debiopharm (Debio 1562 + Rituximab), Seagen\/Takeda (ADCETRIS + lenalidomide + rituximab), Merck (Zilovertamab vedotin + BR) <\/strong>and<strong> <\/strong>others.<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"608\">\n\t<colgroup>\n\t\t<col width=\"129\">\n\t\t<col width=\"195\">\n\t\t<col width=\"142\">\n\t\t<col width=\"142\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"4\" style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#bfe6ff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:129px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Comparison of results: POLIVY vs.<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\"> <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ZYNLONTA in 3L+<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:129px\">&nbsp;<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:195px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Number of Patients&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:142px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ORR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:142px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CRR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:129px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">POLIVY+ BR<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:195px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"background-color:#ffffff\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">40<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:142px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">45%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:142px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">40%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:129px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ZYNLONTA<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:195px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">145<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:142px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">48.3%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 7px 0px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:142px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">24.1%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125348\/Market-Share-of-ADCs-in-2023.png\" alt=\"Market Share of ADCs in 2023\" class=\"wp-image-22505\" width=\"477\" height=\"280\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125348\/Market-Share-of-ADCs-in-2023.png 953w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125348\/Market-Share-of-ADCs-in-2023-300x176.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125348\/Market-Share-of-ADCs-in-2023-150x88.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125348\/Market-Share-of-ADCs-in-2023-768x450.png 768w\" sizes=\"(max-width: 477px) 100vw, 477px\" \/><\/figure>\n\n\n\n<p>In conclusion, antibody-drug conjugates (ADCs) have revolutionized the field of oncology by providing a targeted and effective approach to treating cancer. The recent approvals of ADCs such as <strong>Roche&#8217;s POLIVY<\/strong> and <strong>ADC Therapeutics&#8217; ZYNLONTA<\/strong> for DLBCL treatment have brought new hope to patients and physicians. POLIVY has shown promising results in the first-line setting and is expected to lead the DLBCL treatment market in terms of revenue. However, competition in the second and third-line settings is expected to increase, with ZYNLONTA likely to maintain a consistent patient share<strong> <\/strong>for at least a few years. ADC Therapeutics\u2019 comprehensive program for DLBCL, including the ongoing <a href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-vs-adc-therapeutics-zynlonta-adc-in-rr-dlbcl\"><strong>Phase III LOTIS-5<\/strong> study of <strong>ZYNLONTA<\/strong><\/a>, is expected to provide an advantage over upcoming therapies such as MONJUVI. As the fight against cancer continues, ADCs are a shining beacon of progress and possibility. The release of several <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape\">new ADCs<strong> <\/strong>in R\/R DLBCL treatment<\/a> is likely to affect<strong> <\/strong>the market share of other unique emerging classes, such as bispecific antibodies, cancer vaccines, and BTK inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1682665790215\"><strong class=\"schema-faq-question\"><strong>1. What is diffuse large B-cell lymphoma?<\/strong><\/strong> <p class=\"schema-faq-answer\">Diffuse Large B-cell Lymphoma (DLBCL) is the most prevalent type of non-Hodgkin&#8217;s lymphoma that can develop in lymph nodes or outside the lymphatic system (for example, in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain).\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1682665800142\"><strong class=\"schema-faq-question\"><strong>2. What are the DLBCL symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">DLBCL symptoms include painless, fast swelling in the neck, underarms, or groin produced by swollen lymph nodes. The swelling may be uncomfortable for some people. Night sweats, fever, and unexpected weight loss are some other DLBCL symptoms. Patients may experience weariness, appetite loss, shortness of breath, or discomfort.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1682665825897\"><strong class=\"schema-faq-question\"><strong>3. How is DLBCL diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">A tissue sample is required for a definite DLBCL diagnosis. Because DLBCL is a blood cancer, it is critical to seek any symptoms of lymphoma throughout the body. This is commonly accomplished with a positron emission tomography (PET) scan. A morphological DLBCL diagnosis should be validated in all patients by immunophenotypic investigations, either immunohistochemistry (IHC) or flow cytometry, or a combination of both techniques.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1682665838046\"><strong class=\"schema-faq-question\"><strong>4. What are the current DLBCL treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">DLBCL treatment is often initiated quickly after diagnosis with the goal of achieving a long-term remission or cure. Most treatments still rely on a combination of chemotherapy and a monoclonal antibody targeting CD20. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the most often used combination chemotherapy regimen for DLBCL. It is normally administered in 21-day cycles. Etoposide (VePesid, Toposar, Etopophos) is sometimes combined with the R-CHOP regimen, resulting in the R-EPOCH medication combination. Radiation therapy is sometimes used in DLBCL treatment.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-1024x256.png\" alt=\"Diffuse Large B-cell Lymphoma Market Outlook \" class=\"wp-image-22506\" width=\"768\" height=\"192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28125513\/Diffuse-Large-B-cell-Lymphoma-Market-Outlook.png 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of antibody-drug conjugates (ADCs). These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them together. The result is a powerful therapeutic agent that can precisely target [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":22511,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":6,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[60,61,63,78,18620,20043,20635,20636,524,20637],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-22502","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-adc","tag-adc-therapeutics","tag-adcs","tag-antibody-drug-conjugates","tag-dlbcl","tag-dlbcl-treatment","tag-polivy","tag-polivy-r-chp","tag-roche","tag-zylnonta","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Roche\u2019s POLIVY FDA Approval in First-line DLBCL Treatment<\/title>\n<meta name=\"description\" content=\"Recent approvals of ADCs for DLBCL treatment, such as Roche&#039;s POLIVY &amp; ADC Therapeutics&#039; ZYNLONTA, given patients &amp; physicians renewed hope.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche\u2019s POLIVY FDA Approval in First-line DLBCL Treatment\" \/>\n<meta property=\"og:description\" content=\"Recent approvals of ADCs for DLBCL treatment, such as Roche&#039;s POLIVY &amp; ADC Therapeutics&#039; ZYNLONTA, given patients &amp; physicians renewed hope.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-28T12:20:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-24T04:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130024\/roche-polivy-adc-for-dlbcl-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche\u2019s POLIVY FDA Approval in First-line DLBCL Treatment","description":"Recent approvals of ADCs for DLBCL treatment, such as Roche's POLIVY & ADC Therapeutics' ZYNLONTA, given patients & physicians renewed hope.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment","og_locale":"en_US","og_type":"article","og_title":"Roche\u2019s POLIVY FDA Approval in First-line DLBCL Treatment","og_description":"Recent approvals of ADCs for DLBCL treatment, such as Roche's POLIVY & ADC Therapeutics' ZYNLONTA, given patients & physicians renewed hope.","og_url":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-04-28T12:20:33+00:00","article_modified_time":"2023-05-24T04:02:47+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130024\/roche-polivy-adc-for-dlbcl-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment","url":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment","name":"Roche\u2019s POLIVY FDA Approval in First-line DLBCL Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130024\/roche-polivy-adc-for-dlbcl-treatment.png","datePublished":"2023-04-28T12:20:33+00:00","dateModified":"2023-05-24T04:02:47+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Recent approvals of ADCs for DLBCL treatment, such as Roche's POLIVY & ADC Therapeutics' ZYNLONTA, given patients & physicians renewed hope.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665790215"},{"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665800142"},{"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665825897"},{"@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665838046"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130024\/roche-polivy-adc-for-dlbcl-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130024\/roche-polivy-adc-for-dlbcl-treatment.png","width":772,"height":482,"caption":"roche-polivy-adc-for-dlbcl-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665790215","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665790215","name":"1. What is diffuse large B-cell lymphoma?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Diffuse Large B-cell Lymphoma (DLBCL) is the most prevalent type of non-Hodgkin's lymphoma that can develop in lymph nodes or outside the lymphatic system (for example, in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain).\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665800142","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665800142","name":"2. What are the DLBCL symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"DLBCL symptoms include painless, fast swelling in the neck, underarms, or groin produced by swollen lymph nodes. The swelling may be uncomfortable for some people. Night sweats, fever, and unexpected weight loss are some other DLBCL symptoms. Patients may experience weariness, appetite loss, shortness of breath, or discomfort.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665825897","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665825897","name":"3. How is DLBCL diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"A tissue sample is required for a definite DLBCL diagnosis. Because DLBCL is a blood cancer, it is critical to seek any symptoms of lymphoma throughout the body. This is commonly accomplished with a positron emission tomography (PET) scan. A morphological DLBCL diagnosis should be validated in all patients by immunophenotypic investigations, either immunohistochemistry (IHC) or flow cytometry, or a combination of both techniques.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665838046","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/roche-polivy-adc-for-dlbcl-treatment#faq-question-1682665838046","name":"4. What are the current DLBCL treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"DLBCL treatment is often initiated quickly after diagnosis with the goal of achieving a long-term remission or cure. Most treatments still rely on a combination of chemotherapy and a monoclonal antibody targeting CD20. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is the most often used combination chemotherapy regimen for DLBCL. It is normally administered in 21-day cycles. Etoposide (VePesid, Toposar, Etopophos) is sometimes combined with the R-CHOP regimen, resulting in the R-EPOCH medication combination. Radiation therapy is sometimes used in DLBCL treatment.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/28130024\/roche-polivy-adc-for-dlbcl-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ADC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ADC Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ADCs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DLBCL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DLBCL Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">POLIVY<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">POLIVY + R-CHP<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ZYLNONTA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ADC<\/span>","<span class=\"advgb-post-tax-term\">ADC Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">ADCs<\/span>","<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">DLBCL<\/span>","<span class=\"advgb-post-tax-term\">DLBCL Treatment<\/span>","<span class=\"advgb-post-tax-term\">POLIVY<\/span>","<span class=\"advgb-post-tax-term\">POLIVY + R-CHP<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">ZYLNONTA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 28, 2023","modified":"Updated on May 24, 2023"},"absolute_dates_time":{"created":"Posted on Apr 28, 2023 5:50 pm","modified":"Updated on May 24, 2023 9:32 am"},"featured_img_caption":"roche-polivy-adc-for-dlbcl-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=22502"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22502\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/22511"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=22502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=22502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=22502"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=22502"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=22502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}